adxs11-001 immunotherapy targeting hpv-e7: updated survival...
Post on 12-Jan-2020
4 Views
Preview:
TRANSCRIPT
ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and safety data from a
Phase 2 study in Indian women with recurrent cervical cancer
Robert Petit1 and Partha Basu2
1Advaxis, Inc. Princeton, NJ 2Chittaranjan National Cancer Institute, Kolkata, India
Abstract
Life Cycle of Lm in APC
Lm-LLO Immunotherapy Safety: Frequency of SAEs in 110 patient Phase 2: ADXS11-001 vs. Chemotherapy
Overall Survival
Lm-LLO-E7-15 Best Response Data
ConclusionsCase Study: Patient 110-002
Landmark Survival Duration of Response (PFS)
Overall Survival: Aggressive vs. Non-
Aggressive Disease
Response by Aggressiveness of Disease &
Treatment Group
Lm-LLO-E7-015: A Randomized Phase 2 Study to Assess the Safety & Efficacy of
ADXS-HPV +/- cisplatin Treatment for Recurrent Cervical Cancer
Trial Design: Lm-LLO-E7-15
Safety
top related